Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

Nature Genetics

Volumn 47, Issue 3, 2015, Pages 263-266

  Xu, Heng ^a,b   Robinson, Giles W ^a   Huang, Jie ^a   Lim, Joshua Yew Suang ^a,c   Zhang, Hui ^a   Bass, Johnnie K ^a   Broniscer, Alberto ^a   Chintagumpala, Murali ^d   Bartels, Ute ^e   Gururangan, Sri ^f   Hassall, Tim ^g   Fisher, Michael ^h   Cohn, Richard ⁱ   Yamashita, Tetsuji ^a   Teitz, Tal ^a   Zuo, Jian ^a   Onar Thomas, Arzu ^a   Gajjar, Amar ^a   Stewart, Clinton F ^a   Yang, Jun J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SICHUAN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLPHOSPHATASE; ACYLPHOSPHATASE 2; CISPLATIN; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; ANTINEOPLASTIC AGENT;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; DISEASE SEVERITY; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEARING IMPAIRMENT; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; OTOTOXICITY; PHARMACOGENOMICS; PRIORITY JOURNAL; RADIATION DOSE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; BRAIN NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; INFANT; PRESCHOOL CHILD; PROCEDURES;

ACID ANHYDRIDE HYDROLASES; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD, PRESCHOOL; CISPLATIN; CLINICAL TRIALS AS TOPIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEARING LOSS; HUMANS; INFANT; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84924066642     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3217     Document Type: Article

References (36)

1. Cheung, N.V. & Heller, G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J. Clin. Oncol. 9, 1050-1058 (1991).
2. Perilongo, G. et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N. Engl. J. Med. 361, 1662-1670 (2009).
3. Williams, S.D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435-1440 (1987).
4. Brock, P.R. et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 30, 2408-2417 (2012).
5. Langer, T., am Zehnhoff-Dinnesen, A., Radtke, S., Meitert, J. & Zolk, O. Understanding platinum-induced ototoxicity. Trends Pharmacol. Sci. 34, 458-469 (2013).
6. Qaddoumi, I. et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J. Clin. Oncol. 30, 1034-1041 (2012).
7. Dean, J.B. et al. Hearing loss in pediatric oncology patients receiving carboplatincontaining regimens. J. Pediatr. Hematol. Oncol. 30, 130-134 (2008).
8. Kushner, B.H., Budnick, A., Kramer, K., Modak, S. & Cheung, N.K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107, 417-422 (2006).
9. Chen, W.C. et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106, 820-829 (2006).
10. Li, Y., Womer, R.B. & Silber, J.H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40, 2445-2451 (2004).
11. Oldenburg, J., Kraggerud, S.M., Cvancarova, M., Lothe, R.A. & Fossa, S.D. Cisplatininduced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708-714 (2007).
12. Fouladi, M. et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J. Clin. Oncol. 26, 3749-3755 (2008).
13. Travis, L.B. et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J. Natl. Cancer Inst. 106, dju044 (2014).
14. Mukherjea, D. & Rybak, L.P. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 12, 1039-1050 (2011).
15. Gurney, J.G. et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-oncol. 16, 848-855 (2014).
16. Ross, C.J. et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
17. Pussegoda, K. et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94, 243-251 (2013).
18. Yang, J.J. et al. The role of inherited TPMT and COMT genetic variation in cisplatininduced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-259 (2013).
19. Lanvers-Kaminsky, C. et al. Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity. Clin. Pharmacol. Ther. 96, 156-157 (2014).
20. Ratain, M.J., Cox, N.J. & Henderson, T.O. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin. Pharmacol. Ther. 94, 631-635 (2013).
21. Boddy, A.V. Genetics of cisplatin ototoxicity: confirming the unexplained? Clin. Pharmacol. Ther. 94, 198-200 (2013).
22. Landier, W. et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales-a report from the Children's Oncology Group. J. Clin. Oncol. 32, 527-534 (2014).
23. Bass, J.K. et al. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr. Blood Cancer 61, 601-605 (2014).
24. Won, H.H. et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118, 2828-2836 (2012).
25. Oguri, T. et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int. J. Clin. Pharmacol. Ther. 51, 475-481 (2013).
26. Degl'Innocenti, D. et al. Acylphosphatase expression during macrophage differentiation and activation of U-937 cell line. Biochimie 81, 1031-1035 (1999).
27. Liu, H. et al. Characterization of transcriptomes of cochlear inner and outer hair cells. J. Neurosci. 34, 11085-11095 (2014).
28. Fuchs, P.A. A 'calcium capacitor' shapes cholinergic inhibition of cochlear hair cells. J. Physiol. (Lond.) 592, 3393-3401 (2014).
29. Thomas, A.J. et al. Functional mechanotransduction is required for cisplatininduced hair cell death in the zebrafish lateral line. J. Neurosci. 33, 4405-4414 (2013).
30. Gajjar, A. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 7, 813-820 (2006).
31. Chang, K.W. & Chinosornvatana, N. Practical grading system for evaluating cisplatin ototoxicity in children. J. Clin. Oncol. 28, 1788-1795 (2010).
32. Patterson, N., Price, A.L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2, e190 (2006).
33. Potter, D.M. A permutation test for inference in logistic regression with small- and moderate-sized data sets. Stat. Med. 24, 693-708 (2005).
34. Fine, J.P. & Gray, R.J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999).
35. Huang, R.S. et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81, 427-437 (2007).
36. Choy, E. et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 4, e1000287 (2008).